Back to Search Start Over

Final progression-free survival (PFS) analyses for lanreotide autogel/depot 120 mg in metastatic enteropancreatic neuroendocrine tumors (NETs): The CLARINET extension study

Final progression-free survival (PFS) analyses for lanreotide autogel/depot 120 mg in metastatic enteropancreatic neuroendocrine tumors (NETs): The CLARINET extension study

Authors :
Lucy Wall
Catherine Lombard-Bohas
Xuan Mai Truong Thanh
Jaume Capdevila
Eva Sedlackova
Marianne Pavel
Guido Rindi
Markus Raderer
Martyn Caplin
Alexandria T. Phan
Edward M. Wolin
Nilani Liyanage
Jarosław B. Ćwikła
Philippe Ruszniewski
Guillaume Cadiot
Source :
Journal of Clinical Oncology. 35:4089-4089
Publication Year :
2017
Publisher :
American Society of Clinical Oncology (ASCO), 2017.

Abstract

4089 Background: In the CLARINET core study, lanreotide Autogel (LAN) 120 mg deep sc monthly significantly improved PFS vs PBO in metastatic grade-1/2 enteropancreatic NETs. An interim analysis of patients with stable disease (SD) in the core study continuing LAN in the open-label extension (OLE, of which safety was primary objective) showed continued antitumor effects. Here, we report final LAN PFS analyses for subgroups according to tumor origin and prior therapy. Methods: In the core study, patients with metastatic well/moderately differentiated non-functioning (N-F) enteropancreatic NETs, Ki-67

Details

ISSN :
15277755 and 0732183X
Volume :
35
Database :
OpenAIRE
Journal :
Journal of Clinical Oncology
Accession number :
edsair.doi...........f9e8fb06a4b35bba5eb1b4b59b703fa8
Full Text :
https://doi.org/10.1200/jco.2017.35.15_suppl.4089